TNF Inhibitor denied due to quantity / dose limits by Highmark?

Highmark uses Prime Therapeutics PBM. Adalimumab biosimilar preferred (Cyltezo/Hyrimoz/Yusimry). Step therapy through preferred biosimilar required for new starts; existing patients on Humira may grandfather.

Highmark Continuity of Care provisions — 90-day grandfather for established therapy. Cite Prime Therapeutics PA exception process. ACR 2019 Position Statement opposes non-medical switching of stable patients.

## Why Highmark Limits Quantity for TNF Inhibitors — and Why You Can Appeal

TNF inhibitors (tumor necrosis factor inhibitors) are biologic medications used across several serious inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, and plaque psoriasis. Highmark, like most major insurers, applies quantity limits to TNF inhibitors to align dispensing with what it considers standard dosing intervals. A denial citing quantity limits typically means your pharmacy claim exceeded the number of units, vials, pens, or prefilled syringes Highmark permits per fill or per defined period.

## Why This Is Appealable

Quantity limits are not clinical judgments — they are administrative guardrails. When your prescriber has determined that your condition requires a dosing schedule that exceeds those limits, the insurer must evaluate the medical justification before refusing coverage. Under the Affordable Care Act (ACA §2719) and ERISA §503, you have the right to a full-and-fair internal review followed, if needed, by an independent external review. The external review window is generally available within approximately four months of a denial. An expedited review — often resolved within 72 hours — is available when your health would be seriously jeopardized by waiting.

## The Appeal Process and Timeline

1. Request the denial letter and Explanation of Benefits (EOB) — confirm the exact quantity limit cited and the policy number governing it. 2. File an internal appeal — Highmark's member handbook specifies the deadline (typically 180 days from denial). Submit in writing, keeping copies. 3. Request an external review — if the internal appeal is denied, you can escalate to an independent review organization (IRO) certified in your state. 4. Expedited track — if your prescriber certifies that standard timing would cause serious harm, request expedited review at both stages.

## Documentation to Gather

• Diagnosis confirmation: current chart notes, specialist letters, and diagnostic records establishing the condition being treated.
• Prescriber's medical-necessity letter: your physician should explain specifically why the prescribed quantity and interval are medically required for your case, citing your clinical course and any prior treatment failures.
• Prior treatment history: dates, doses, and documented outcomes of all prior therapies tried, including why each was discontinued.
• Clinical severity documentation: objective measures from your chart (lab values, imaging, validated scoring tools) showing disease activity — without your appeal asserting specific thresholds, your chart documents the severity.
• FDA-approved prescribing label: obtain the current label and identify the approved dosing range your prescription falls within.
• Highmark's published coverage policy: request the specific medical or pharmacy policy governing TNF inhibitor quantity limits, then map each requirement to your chart evidence.

## Criteria-Mapping Structure

For each requirement in Highmark's quantity-limit policy, create a two-column response:

| Policy Requirement | Supporting Chart Evidence | |---|---| | Approved indication | [Diagnosis from chart] | | Dosing consistent with labeling | [Prescriber explanation + label reference] | | Quantity medically necessary | [Prescriber letter citing clinical rationale] |

A focused, evidence-mapped appeal significantly improves your chances of reversal.